Rhythm (Nasdaq:IRTC) reported first-quarter financial results that came in ahead of the consensus forecast on Wall Street.
The blended fair value estimate for iRhythm Holdings has been trimmed from US$199.57 to US$195.00, a modest reset that reflects updated modeling assumptions rather than a wholesale rewrite of the ...
Two retrospective studies detected arrhythmias beyond 48 hours in 30% of patients post cardiac ablation and in 60% of ...
Rhythm (Nasdaq:IRTC) today announced findings from two real-world analyses supporting its long-term heart monitoring ...
M, assuming sustained core demand while maintaining a conservative stance on newer, emerging channels. The next-generation ...
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio ® long-term continuous ECG monitoring (LTCM) ...
Hosted on MSN
iRhythm lifts 2026 outlook after strong Q1 growth
iRhythm Technologies posted $199.4 million in Q1 revenue, a 26% year-over-year increase, and raised its 2026 revenue and adjusted EBITDA margin guidance. The company credited broad adoption of its Zio ...
Hosted on MSN
iRhythm raises 2026 forecast after strong Q1 results
iRhythm Technologies increased its 2026 revenue and profit guidance after reporting a 26% year-over-year jump in first-quarter sales, fueled by broader electronic health record integration, AI-driven ...
SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the U.S. launch of its next-generation Zio® monitor and enhanced Zio® long-term continuous ...
The U.S. Food and Drug Administration has issued a warning letter to iRhythm Technologies after inspectors found fault with practices at a facility that makes its heart monitors. According to iRhythm, ...
iRhythm Technologies, Inc. IRTC has received regulatory approval from Japan’s Pharmaceutical and Medical Device Agency for its Zio long-term continuous ECG monitoring (LTCM) system. The Zio system, ...
iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results